CDKN2B and neoplasm: Cdkn2b is often inactivated due to deletion, methylation, or mutation in various tumors, leading to tumor progression and being considered an inhibitor of tumors (Jang et al., 2019; Yang et al., 2021; Hjazi et al., 2023).